Pfizer signed an exclusive licensing deal with China's Starna Therapeutics on November 18, 2026, worth up to $2.6 billion, including $330 million upfront and up to $2.3 billion in milestones. The agreement covers three pre-clinical in vivo CAR-T therapies for autoimmune diseases outside Greater China. The deal follows Pfizer's $10.5 billion agreement with Innovent Biologics in May 2026 and an earlier 2025 deal with 3SBio.
Pfizer-Starna licensing deal
- ▪The three CAR-T therapies Pfizer licensed from Starna Therapeutics for autoimmune diseases have not yet entered human trials as of November 18, 2026
- ▪Starna Therapeutics will receive royalties on sales of any approved products under the Pfizer licensing agreement
- ▪Pfizer struck an exclusive licensing agreement with China's Starna Therapeutics to develop three CAR-T therapies for autoimmune diseases
- ▪Pfizer will pay Starna Therapeutics $330 million upfront under the licensing agreement
- ▪Pfizer could pay Starna Therapeutics up to $2.3 billion more if the treatments meet development, regulatory, and sales milestones
- ▪The Pfizer-Starna licensing deal is worth up to $2.6 billion in total
- ▪The Pfizer-Starna agreement gives Pfizer rights to develop and commercialize three early-stage autoimmune disease programs outside Greater China
CAR-T therapy technology
- ▪In vivo CAR-T therapies are designed to genetically reprogram immune cells directly inside the body to target and eliminate disease-causing immune cells
- ▪Conventional CAR-T treatments involve collecting and re-engineering a patient's cells outside the body before reinfusing them
Pfizer growth strategy
- ▪Pfizer's licensing deal with Starna Therapeutics is part of the company's strategy of partnering with Chinese biotechs to drive growth
- ▪Pfizer is seeking to reignite growth by 2028 while preparing for a wave of patent expirations and continued declines in COVID-related revenue
Story comments
Loading comments…